Compare AbbVie Inc (ABBV) vs Carnival Corp (CCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Carnival Corp — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Carnival Corp trades at $25.67 (market cap $36.54B). The key difference: AbbVie Inc is far larger — about 12.3× Carnival Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CCL | |
|---|---|---|
Market Cap | $449.91B | $36.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $33.99 |
52-Week Low | $184.85 | $23.89 |
Enterprise Value | $513.38B | $60.47B |
Dividend Yield | 2.72% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Carnival Corporation (CCL) trades at $26.68, down 4.41% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamental recovery with revenue growing to $26.62B in 2025 and net income reaching $2.76B. Positive analyst sentiment exists with a $35.45 consensus price target, though near-term headwinds in European demand and cost pressures are noted.
The outlook for CCL is cautiously optimistic. Strong booking trends and debt reduction support long-term growth, but investors face risks from geopolitical issues, fuel costs, and competitive pressures. The stock presents potential upside from current levels if execution continues, but requires monitoring of guidance and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →
